$1.275
-0.048 (-3.77%)Zum Schluss
Profitabilität und Margen von PMVP
Evaluating the bottom line, Pmv Pharmaceuticals, Inc maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -70.93%, provide a clear picture of how effectively PMVP converts its operational activities into shareholder value.
PMVP im Vergleich zur Peergroup
In the context of the broader market, PMVP competes directly with industry leaders such as KZIA and IMDX. With a market capitalization of $96.28M, it holds a significant position in the sector. When comparing efficiency, PMVP's gross margin of N/A stands against KZIA's 100.00% and IMDX's 65.69%. Such benchmarking helps identify whether Pmv Pharmaceuticals, Inc is trading at a premium or discount relative to its financial performance.
Finanzielle Entwicklung von PMV Pharmaceuticals Inc
PMV Pharmaceuticals has reported a consistent net loss, with a net income of -$18.04 million in the latest quarter and a deteriorating ROE of -70.93%. The company has a current ratio of 7.70, indicating adequate liquidity despite the losses.
Financials
Ähnliche Artikel
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
- Santa Claus Rally and the Year-End Stock Market: Investor Guide for Late 2026Santa Claus rally explained: 7-day window stats since 1950, Nov–Dec seasonality, post-midterm 2026 setup, and a risk-managed year-end investing playbook.
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.